Metabolic profiling using HPLC allows classification of drugs according to their mechanisms of action in HL-1 cardiomyocytes
Authors:
- Judith WahrheitJWJudith Wahrheit
- Simone BeckersSBSimone Beckers
- Elmar HeinzleEHElmar Heinzle
- Fozia NoorFNFozia Noor
- 1 April 2011
- journal article
- research article
- Published by Elsevier in Toxicology and Applied Pharmacology
- Vol. 252 (2) , 183-191
Abstract
No abstract availableKeywords
This publication has 65 references indexed in Scilit:
- Multivalent dendrimeric and monomeric adenosine agonists attenuate cell death in HL-1 mouse cardiomyocytes expressing the A3 receptorBiochemical Pharmacology, 2010
- IP3-Induced Cytosolic and Nuclear Ca2+ Signals in HL-1 Atrial Myocytes: Possible Role of IP3 Receptor SubtypesMolecules and Cells, 2010
- Who will take up the gauntlet?EMBO Reports, 2009
- Human embryonic stem cell technologies and drug discoveryJournal of Cellular Physiology, 2009
- Metabolic profiling studies on the toxicological effects of realgar in rats by 1H NMR spectroscopyToxicology and Applied Pharmacology, 2009
- Metabolomic Profiling of Drug Responses in Acute Myeloid Leukaemia Cell LinesPLOS ONE, 2009
- Metabolomics: A Global Biochemical Approach to Drug Response and DiseaseAnnual Review of Pharmacology and Toxicology, 2008
- Myocardial Substrate Metabolism in the Normal and Failing HeartPhysiological Reviews, 2005
- Comparison of tumor necrosis factor-α effect on the expression of iNOS in macrophage and cardiac myocytesPerfusion, 2001
- Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions Potential for pharmacological interventionsCardiovascular Research, 1997